Literature DB >> 15519367

Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.

Takuro Oka1, Takashi Hamamura, Youmei Lee, Shinji Miyata, Toshiaki Habara, Shiro Endo, Hideki Taoka, Shigetoshi Kuroda.   

Abstract

Acute administration of typical and atypical antipsychotics has been reported to induce regionally distinct patterns of c-Fos expression in the rat forebrain. Furthermore, atypical index, the difference in the extent of increased Fos-like immunoreactivity (Fos-LI) in the nucleus accumbens (NAc) shell versus the dorsolateral striatum (DLSt), has been proposed to classify antipsychotics into typical or atypical antipsychotics. The present study was conducted to investigate the atypical properties of 24 antipsychotics that are used in Japan and blonanserin, a novel 5-HT2A and D2 receptor antagonist. We systematically examined the effects of the drugs on Fos-LI in the NAc and DLSt in the rat brain using immunohistochemistry and calculated the atypical index, comparing with those of haloperidol and clozapine. Floropipamide, oxypertine, nemonapride, pimozide and mosapramine, as well as clozapine, olanzapine, quetiapine and risperidone, showed high positive atypical index. Zotepine, perospirone, sulpiride, moperone, sultopride, thioridazine, carpipramine, clocapramine and blonanserin showed moderate ones. In contrast, fluphenazine, bromperidol, timiperone, spiperone, propericiazine, perphenazine, chlorpromazine and levomepromazine had negative atypical index like haloperidol. These results suggest that not only so-called atypical antipsychotics, but also several conventional drugs, possess atypical properties.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15519367     DOI: 10.1016/j.lfs.2004.08.009

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

Review 1.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

2.  Effects of aripiprazole on caffeine-induced hyperlocomotion and neural activation in the striatum.

Authors:  Luara A Batista; Thércia G Viana; Vívian T Silveira; Daniele C Aguiar; Fabrício A Moreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-29       Impact factor: 3.000

3.  Neuroanatomical substrates of the disruptive effect of olanzapine on rat maternal behavior as revealed by c-Fos immunoreactivity.

Authors:  Changjiu Zhao; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2012-08-31       Impact factor: 3.533

Review 4.  Blonanserin: a review of its use in the management of schizophrenia.

Authors:  Emma D Deeks; Gillian M Keating
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

5.  Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine.

Authors:  Taro Kishi; Shinji Matsunaga; Yuki Matsuda; Nakao Iwata
Journal:  Neuropsychiatr Dis Treat       Date:  2014-12-10       Impact factor: 2.570

6.  Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor.

Authors:  Avril Pereira; Betty Zhang; Peter Malcolm; Anthony Sugiharto-Winarno; Suresh Sundram
Journal:  BMC Neurosci       Date:  2014-02-20       Impact factor: 3.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.